Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2023Cited by 62
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML projectClaudia Sargas, Pau Montesinos, Yanira Florido-Ortega et al.|Haematologica|2020Cited by 37
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA RegistryClaudia Sargas, Rosa Ayala, María José Larráyoz et al.|Cancers|2023Cited by 30
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry StudyRosa Ayala, Pau Montesinos, Gonzalo Carreño‐Tarragona et al.|Cancers|2022Cited by 12
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Pau Montesinos, Rebeca Rodríguez‐Veiga et al.|Cancers|2025Cited by 2